Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated erectile dysfunction
(ED) drug branded “Mango,” is excited to announce the official
launch of its affiliate marketing program via its newly designed
website at www.MangoRevenue.com.
“Affiliate marketing programs have been shown to
drive huge gains in trust and awareness when properly marketed and
executed correctly and we believe that this strategy will add
additional brand recognition and notoriety for our MangoRx brand,”
remarked Jacob Cohen, CEO and Co-Founder of MangoRx. “As affiliate
marketers are compensated based on sales and performance, this new
and dynamic channel is perfect for growing additional topline
revenues while at the same time reducing the upfront cash burden
that has traditionally been spent on digital marketing and
advertising. We believe that a well-executed and marketed affiliate
marketing program can lead to driving more than roughly 20% of the
Company’s overall gross revenue.”
According to a recent affiliate marketing
survey, the global affiliate marketing industry is worth
over $17 billion and is expected to grow to a market size
of $27.78 billion by 2027. Additionally, 81% of
brands use affiliate programs to boost brand awareness and
drive sales with these affiliate marketing programs accounting
for 16% of all internet orders in the U.S. Major
brands get 5% to 25% of their overall online sales from
affiliate marketing with 20% of brand marketers claiming
affiliate marketing is their most successful revenue driving
channel.
The Company has partnered with one of the top
marketing agencies and software providers in the affiliate
marketing industry to ensure all the building blocks are in place
to supercharge its topline future growth.
MangoRx has selected Impact Radius
(www.impact.com), a company trusted by 1,000s of leading
global brands such as such as Kohl’s, Best Buy, Uber, Microsoft,
Target, Levi’s, Adidas, Yeti, and Gap, among others, as its premier
affiliate automation and influencer management platform. Impact
Radius has worked with companies providing cutting-edge backend
software management for affiliate marketing programs as well as an
actively managed recruiting database of more than 7 million
influencers interested in helping emerging brands blossom and
thrive. Impact Radius will also handle the management of toolkits
for affiliate marketing partners.
Furthermore, MangoRx has partnered with Hamster
Garage (www.hamstergarage.com), a partnerships and affiliate
management agency to assist MangoRx in building and managing its
partnership programs. Hamster Garage has taken on over 40,000
affiliate marketing partner relationships to help partner-clients
raise over $9.3 billion, with its average program driving 300%
efficiency across the project. Hamster Garage will drive affiliate
discovery and interest, coordinating and managing affiliate
relationships for MangoRx.
Cohen added, “we have complete confidence that
affiliate marketing represents a new avenue for driving accelerated
sales growth for MangoRx and its stakeholders, which is our number
one priority. We believe we have a top-tier, premium product. Now
we have top-tier partners and a viable strategy for massively
augmenting our visibility and brand value. We look forward to
providing additional updates on this program soon.”
To learn more about the perks and benefits of
the MangoRx affiliate marketing program, visit us at
www.MangoRevenue.com for more information.
About Mango
Created using a special formulation featuring
either the same active ingredient as in Cialis™ (Tadalafil) or
Viagra™ (Sildenafil), each part of the Mango formulation plays a
critical role in helping men achieve optimum performance. We
believe the key to our success lies in our unique blend of
ingredients, which are used in U.S. Food and Drug Administration
(“FDA”) approved drugs. Mango contains a combination of either
Sildenafil or Tadalafil along with Oxytocin and L-Arginine that
have been traditionally used to treat sexual dysfunction.
Mango is a prescription medication that must be
approved by a physician. After an individual has completed an
online tele-health visit, our network of medical providers will
review and approve a prescription if medically appropriate. Mango
is a rapidly dissolved tablet (RDT) that is absorbed orally. For
best results, we advise taking Mango at least 15 minutes before
engaging in sexual activity. Sildenafil and Tadalafil, one of the
main ingredients in Mango, typically have effects that last up to 4
and 36 hours, respectively.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on
developing, marketing, and selling a variety of men's health and
wellness products and services via a secure telemedicine platform.
To date, the Company has identified men's wellness telemedicine
services and products as a growing sector and especially related to
the area of erectile dysfunction (ED). The Company has developed a
new brand of ED product under the brand name "Mango" (think: "Man,
Go!").
For more information, please visit
www.MangoRx.com.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen and President, Jonathan Arango, combined have majority voting
control over the Company; risks related to the significant number
of shares in the public float, our share volume, the effect of
sales of a significant number of shares in the marketplace, and the
fact that the majority of our shareholders paid less for their
shares than the public offering price of our common stock in our
recent initial public offering; the fact that we have a significant
number of outstanding warrants to purchase shares of common stock
at $1.00 per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended June 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social
media: https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
Or just click here to see why Orange is the new
Blue: https://www.mangorx.com
FOR PUBLIC RELATIONS Lucky Break Public
Relations Sahra Simpson Sahra@luckybreakpr.com (323) 602-0091 ext.
704
FOR INVESTOR RELATIONS Mangoceuticals Investor
Relations Email: investors@mangorx.com
MEDIA CONTACT PHOENIX MGMT Marketing &
Consulting info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Jul 2024 to Jul 2024
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Jul 2023 to Jul 2024